87 results about "Integrin" patented technology

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The application belongs to the field of biomedical application, and more particularly relates to a cell fluorescence probe anchoring cell integrin, and a preparation method and application thereof. The cell fluorescence probe comprises a polypeptide complex, a fluorescent molecule and a cyclodextrin unit, the polypeptide complex comprises a cysteine-containing peptide, a peptide containing a bonding group and a targeting peptide which are connected in any order, the cyclodextrin unit contains a carbon-carbon double bond functional group, and is combined with the cysteine-containing peptide through a click reaction to form the polypeptide complex, the polypeptide complex is covalently connected to the fluorescent molecule through the bonding group, and the fluorescent molecule is an aggregation-induced emission compound. The double bond functional group of the modified cyclodextrin is bonded to the sulfhydryl group of the terminal cysteine of the polypeptide through a click reaction, and the sulfhydryl group of the terminal cysteine of the polypeptide is bonded to the double bond functional group of the modified cyclodextrin through a click reaction, so that the cyclodextrin is improved to protect the fluorescent molecule and prolong the fluorescent time effectiveness of the fluorescent imaging reagent.

The present disclosure relates, in part, to radiopharmaceuticals that target integrin, such αvβ6, their pharmaceutical compositions, and their use in imaging, diagnosing, and treatment of conditions associated with overexpression of integrins as well as to methods of making these compositions, including high purity 61Cu[Cu] radiopharmaceuticals that target integrins.

Disclosed are small molecule inhibitors of αvβ8 integrin, and methods of using them to treat a number of diseases and conditions.

The invention provides a method for improving stem cell dryness of mesenchymal stem cells and a compound and a composition thereof, the method for improving the stem cell dryness of the mesenchymal stem cells comprises the following steps: treating the mesenchymal stem cells with an active substance, activating an integrin-FAK-Src pathway, enhancing the phosphorylation level of FAK and Src proteins, and further activating a downstream PI3K / Akt pathway, so that the stem cell dryness of the mesenchymal stem cells is improved, and the stem cell dryness of the mesenchymal stem cells is improved. The cell dryness of the mesenchymal stem cells is improved. The research confirms that the COL21 has a promoting effect on MSC proliferation, and meanwhile, the COL21 is confirmed to promote expression of four stemness markers including Oct-4, Klf4, Nanog and Sox2 in MSC, so that the stemness of MSC stem cells is improved.

The application relates to a recombinant type I collagen and application thereof, which utilizes the characteristics of Pichia pastoris capable of secreting and expressing recombinant proteins, secretes the recombinant type I collagen on the culture medium supernatant, and reduces the difficulty of protein purification. In addition, the integrin site RGD is inserted into the collagen to form a recombinant type I collagen with high stability and high expression. According to the relative proliferation of cells and the relative adhesion experiment of cells, it can be seen that the recombinant type I collagen has the effects of promoting the proliferation of skin fibroblasts, improving the skin, promoting wound healing, promoting the adhesion of fibroblasts in the skin layer and the like. Therefore, the recombinant type I collagen has great potential applications in the fields of skin care and beauty, medical treatment and the like.

This disclosure relates to novel chemical compounds and methods useful for inhibiting αvβ8 integrin.

Disclosed herein are methods and compositions for disrupting the interaction between galectin-3 and insulin receptor or integrins. Also disclosed herein are methods and compositions for treating a disease or disorder in a subject, such as diabetes, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

The application belongs to the field of biological medicine, and relates to an anti-human integrin CD103 nanobody and application. The anti-human integrin CD103 nanobody comprises three complementarity determining regions CDR1, CDR2 and CDR3; wherein the amino acid sequence of CDR1 is a sequence or a high homology sequence shown in one of SEQ ID NO: 1 to SEQ ID NO: 6, the amino acid sequence of CDR2 is a sequence or a high homology sequence shown in one of SEQ ID NO: 7 to SEQ ID NO: 12, and the amino acid sequence of CDR3 is a sequence or a high homology sequence shown in one of SEQ ID NO: 13 to SEQ ID NO: 18. 18 The F-CYNB nanobody probe can be applied to targeted imaging of cardiac myocardial fibrosis.

The invention discloses application of irisin in treatment of acute lung injury / acute respiratory distress syndrome. The research finds that the plasma irisin level is obviously reduced in ARDS patients, and the survival prognosis of the patients with the lower irisin level is poorer. Neutrophil as the most inflammatory cells is a cause for promoting lung tissue injury. Further analysis finds that the level of irisin is in negative correlation with the number of circulating neutrophils, and irisin incubation can significantly reduce in-vitro survival promoting (apoptosis delay) phenotypes of neutrophils in ARDS mouse alveolar lavage fluid. Iris receptor integrin alphaVbeta5 inhibitor treatment can promote neutrophil infiltration and aggravate an ARDS process. The invention provides a novel therapeutic drug and strategy for the treatment of acute lung injury / acute respiratory distress syndrome.

The present invention relates to the use of an antibody or an immunologically active fragment thereof, which specifically binds to integrin β2, as an immuno-oncology agent. The chimeric and humanized antibodies of the present invention specifically bind to integrin β2, which is a tumor-specific antigen and is expressed on the cell membrane of M2 tumor-associated macrophages, and thus can be used as an antibody therapeutic agent for cancer treatment using a cancer cell death mechanism by immune cell activation, an antibody therapeutic agent for cancer treatment, or a cell therapeutic agent for cancer treatment, and can also be used for cancer diagnosis.

The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and / or preventing or ameliorating at least one motor deficit in a subject in need thereof, such as in a subject with α-synucleinopathy, using the novel irisin peptides to modulate irisin-induced integrin signaling. The novel irisin peptides can also be used in methods for increasing expression of brain-derived neurotrophic factor (BDNF), and / or treating or preventing neurological diseases or disorders that would benefit from decreased neuronal cell death and / or increased neuronal survival in a subject. In addition, the novel irisin peptides may be used in methods for preventing or treating muscular atrophy or muscular dystrophy.

The application discloses a kind of fusion polypeptide SynExo for targeted delivery and its engineering exosome preparation method.The fusion polypeptide includes PDGFR beta transmembrane domain (FIASFFLAVVTLLVLLYF), photocontrol cross-linking site 4-azidophenylalanine (AzF) and double-targeting peptide CRGDKGPDC, is connected in series by flexible linker GGGGS, realizes the efficient anchoring, accurate targeting and space-time controllable delivery of exosome.The high hydrophobicity (GRAVY value +2.3) of PDGFR beta transmembrane domain makes its anchoring efficiency increase by 2.7 times, AzF generates azinome intermediate under 365nm light to realize irreversible cross-linking, double-targeting peptide targets integrin αvβ3 and ECM1 by cRGD (Kd=25nM) and KGPDC (Kd=1.2nM) synergistically, and penetration depth reaches 180 μm.Engineering exosome realizes AzF accurate incorporation by lentivirus packaging combined with orthogonal tRNA system, and in diabetic ulcer model, targeted enrichment efficiency reaches 6.8 times of unmodified group, and wound closure rate is 92.5%, which is significantly better than that of control group.The application provides an innovative platform for targeted treatment of diseases such as tumors and diabetic ulcers.

The application belongs to the field of biological medicine, and relates to an anti-mouse integrin CD103 nanobody and application. The anti-mouse integrin CD103 nanobody comprises three complementarity determining regions CDR1, CDR2 and CDR3; wherein the amino acid sequence of CDR1 is a sequence or a high homology sequence shown in one of SEQ ID NO:1 to SEQ ID NO:4, the amino acid sequence of CDR2 is a sequence or a high homology sequence shown in one of SEQ ID NO:5 to SEQ ID NO:8, and the amino acid sequence of CDR3 is a sequence or a high homology sequence shown in one of SEQ ID NO:9 to SEQ ID NO:12. The application relates to the anti-mouse integrin CD103 nanobody and a preparation method thereof 18 The F-CYNB nanobody probe can realize targeted imaging of myocardial fibrosis, immune imaging of mouse tumors, and prediction of the effect of tumor immunotherapy.

This invention belongs to the field of bioengineering and functional skincare formulation technology, specifically relating to a dual-effect anti-aging freeze-dried composition for reversing photoaging and endogenous aging, and its application. The composition of this invention, based on the mass percentage of the original solution before freeze-drying, contains 3-8% photorepair enzymes, 15-25% recombinant collagen, 62-75% ternary freeze-drying protectant, 0.5-0.9% sodium chloride, and the balance being buffer solution. The ternary freeze-drying protectant includes fillers, vitreous-forming agents, and antioxidants. This invention repairs UV-induced DNA damage (such as cyclobutanepyrimidine dimers) through photorepair enzymes, while simultaneously utilizing recombinant collagen to remodel the extracellular matrix microenvironment, providing integrin adhesion signals, thus synergistically reversing skin photoaging and endogenous aging. The final composition obtained by this invention has good reconstitution properties and can be used to prepare anti-aging cosmetics such as lotions, serums, and creams, achieving highly effective and safe anti-aging effects on the skin.

The present disclosure provides α, including compounds according to formula (I) and pharmaceutically acceptable salts thereof: v The present invention relates to novel compounds and methods useful for inhibiting β8 integrins. [Formula 1] JPEG2026506652000857.jpg57164

The invention provides an antibody for resisting human disintegrin and metalloproteinase 9 (ADAM9) and application of the antibody. The antibody provided by the invention can be specifically combined with human ADAM9, can rapidly internalize into tumor cells, can effectively block the metalloproteinase activity of ADAM9, and is coupled with a small-molecule cytotoxic compound to prepare a targeted killing antibody drug conjugate; the invention has important application potential in the aspects of tumor targeted therapy, targeted killing ADC drug development, targeted and immune combined therapy, bispecific or multispecific antibody development and the like.

Provided herein are variant [alpha] 4 [beta] 7 integrin antibodies and methods of use.

Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin ανβ6 in a specimen.

The invention relates to the technical field of polypeptide drug modification, and discloses a covalent polypeptide coupling drug compound as well as preparation and application thereof. According to the present invention, the polypeptide coupling drug SuFEx-RGD-VC-DOX is constructed, the cyclopeptide 9h is converted into the intermediate SuFEx-RGD-Alkyne, the adriamycin is converted into the adriamycin pre-linking body N3-VC-DOX through the VC dipeptide and the azide reagent, the connection of the cyclopeptide 9h and the adriamycin is achieved through the SuFEx-RGD-Alkyne and the N3-VC-DOX, and the SuFEx-RGD-VC-DOX is successfully prepared. Experiments prove that the SuFEx-RGD-VC-DOX significantly improves the binding stability of adriamycin and a tumor cell receptor, reduces the off-target rate, has good targeting ability to integrin, realizes precise killing of tumor cells, and has better anti-tumor performance compared with a traditional chemotherapeutic drug DOX.

The present disclosure provides a therapeutic method of treating cancer metastasis by inducing clearance of EVs using a binding agent specific to an EV protein. The method utilizes one or more binding agents specific to EV proteins, where the EV proteins are selected from prostaglandin F2 receptor negative regulator (PTGFRN); basigin (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta-1 (ITGB1); integrin alpha-4 (ITGA4); 4F2 cell-surface antigen heavy chain (SLC3A2); a class of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4); CD13 (aminopeptidase N); MME (neprilysin), ENPP1 (ectonucleotide pyrophosphatase / phosphodiesterase family member 1); and NRP1 (neuropilin-1). Further provided herein includes a pharmaceutical composition for the treatment of cancer metastasis.

The application discloses high-adhesion modified mesenchymal stem cells and application thereof in preparation of a medicine for treating intrauterine adhesion. The modified mesenchymal stem cells are genetically engineered to overexpress integrin alpha 2 subunit and / or integrin alpha 5 subunit, thereby enhancing the adhesion capacity to the extracellular matrix (collagen and fibronectin) of the endometrium. In vitro experiments show that the initial adhesion rate, liquid flushing resistance and anoikis resistance of the modified MSCs are significantly better than those of common MSCs. When used in combination with the "dynamic culture and drug delivery device for intrauterine adhesion treatment" applied by the inventor on the same day, the retention rate of the modified MSCs in the simulated intrauterine dynamic culture environment is significantly improved. Animal experiments show that the modified MSCs in combination with the device can significantly promote endometrial regeneration, inhibit fibrosis and improve the pregnancy rate. The application solves the core bottleneck of low cell retention rate and short survival time in the MSC transplantation treatment of intrauterine adhesion by enhancing the adhesion capacity of the MSCs, and forms a complete treatment scheme in cooperation with the device, thereby having a good clinical application prospect.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

This invention belongs to the field of genetic engineering technology, specifically relating to a recombinant type I collagen, its preparation method, and its applications. Its amino acid sequence is shown in SEQ ID NO.1. The recombinant type I collagen of this invention is based on a short amino acid sequence from natural type I collagen, with the integrin recognition sequence GFPGER added as a repeating unit, repeated multiple times, with a repetition count of 6. The recombinant type I collagen exhibits extremely good hydrophilicity and stability, high adhesion, and does not cause immune rejection when applied to the human body. It can be used in the preparation of tissue engineering materials such as bone implants and bone repair scaffolds.

The present invention relates to an antibodies that bind to the PSI domain of integrin β6, drugs comprising the antibodies, a method for screening for the antibodies, a method for producing the antibodies, a method for treating cancer comprising a step for administering the antibodies, and the like.

The invention discloses a multifunctional medical coupling agent and a preparation method and application thereof, and belongs to the field of medical materials.The coupling agent comprises (1) an electric insulation gel matrix formed by perfluoropolyether oil and fluorinated gel; (2) temperature-responsive nanoparticles which are uniformly dispersed in the gel matrix and have surfaces subjected to hydrophobic modification, wherein the temperature-responsive nanoparticles contain rare earth ions Y < 3 + >, Yb < 3 + > and Er < 3 + >; and (3) fluorinated targeted liposome which is uniformly dispersed in the gel matrix and is modified with sulfhydrylated RGD peptide on the surface, wherein a therapeutic drug is encapsulated in the fluorinated targeted liposome. Wherein the perfluoropolyether oil ensures the electrical insulation safety; the temperature response type nanoparticles emit fluorescence signals, and the fluorescence signals can be inverted into temperature values; the sulfhydrylated RGD peptide recognizes and is combined with tumor angiointegrin alpha v beta 3, so that active targeting can be realized. The multifunctional medical coupling agent disclosed by the invention has multiple functions of electrical insulation safety guarantee, temperature monitoring, targeted drug delivery and the like, and meets the requirements of complex medical scenes.

The purpose of the present invention is to provide a ligand of an integrin [alpha] v [beta] 6 protein receptor capable of binding to the integrin [alpha] v [beta] 6 protein receptor, a conjugate thereof with a molecule to be transported (e.g., an oligonucleotide conjugate, e.g., a ligand-siRNA conjugate), and methods of making and using the same. The present disclosure also relates to compositions containing such ligand conjugates of integrin [alpha] v [beta] 6 protein receptors, methods of making and uses thereof.